Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EVO
Upturn stock ratingUpturn stock rating

Evotec SE ADR (EVO)

Upturn stock ratingUpturn stock rating
$3.82
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: EVO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $5.74

1 Year Target Price $5.74

Analysts Price Target For last 52 week
$5.74 Target price
52w Low $2.84
Current$3.82
52w High $5.64

Analysis of Past Performance

Type Stock
Historic Profit -11.35%
Avg. Invested days 51
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.36B USD
Price to earnings Ratio -
1Y Target Price 5.74
Price to earnings Ratio -
1Y Target Price 5.74
Volume (30-day avg) 6
Beta 1.1
52 Weeks Range 2.84 - 5.64
Updated Date 08/15/2025
52 Weeks Range 2.84 - 5.64
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.51

Earnings Date

Report Date 2025-08-13
When -
Estimate -0.0667
Actual -0.12

Profitability

Profit Margin -20.01%
Operating Margin (TTM) -16.7%

Management Effectiveness

Return on Assets (TTM) -2.4%
Return on Equity (TTM) -16.75%

Valuation

Trailing PE -
Forward PE 59.88
Enterprise Value 1045219684
Price to Sales(TTM) 1.75
Enterprise Value 1045219684
Price to Sales(TTM) 1.75
Enterprise Value to Revenue 1.15
Enterprise Value to EBITDA -21.37
Shares Outstanding 355198016
Shares Floating 130516727
Shares Outstanding 355198016
Shares Floating 130516727
Percent Insiders -
Percent Institutions 2.74

ai summary icon Upturn AI SWOT

Evotec SE ADR

stock logo

Company Overview

overview logo History and Background

Evotec SE was founded in 1993 in Hamburg, Germany. Initially focused on drug discovery technologies, it evolved into a fully integrated drug discovery and development company, offering services and solutions across the drug discovery value chain. The ADR allows US investors to invest in Evotec.

business area logo Core Business Areas

  • EVT Execute: Provides comprehensive drug discovery solutions, including target identification, assay development, high-throughput screening, lead optimization, and pre-clinical development.
  • EVT Innovate: Focuses on proprietary drug discovery programs, often through collaborations with pharmaceutical companies, biotech companies, and academic institutions, targeting areas with unmet medical needs.
  • Just - Evotec Biologics: Offers development, manufacturing, and formulation services for biologics.

leadership logo Leadership and Structure

Dr. Werner Lanthaler is the CEO. The company has a supervisory board and an executive management board. It operates with a decentralized structure, with various sites specializing in different aspects of drug discovery and development.

Top Products and Market Share

overview logo Key Offerings

  • Drug Discovery Services: Provides comprehensive services for drug discovery, including target identification, hit-to-lead optimization, and preclinical development. Market share data is fragmented across various service segments, making a precise overall figure unavailable. Competitors include Charles River Laboratories (CRL), WuXi AppTec (WX), and Labcorp Drug Development (LH).
  • Biologics Development and Manufacturing: Offers services for the development and manufacturing of biologics, including antibodies, proteins, and cell therapies. Market share in this segment is also complex, with significant competition. Competitors include Lonza (LONN.SW), Thermo Fisher Scientific (TMO), and Catalent (CTLT).

Market Dynamics

industry overview logo Industry Overview

The drug discovery services industry is experiencing strong growth, driven by increasing R&D spending by pharmaceutical and biotech companies, the rising complexity of drug targets, and the growing demand for outsourced research services. Biologics development and manufacturing is also rapidly growing.

Positioning

Evotec is a well-positioned player in the drug discovery services market, with a strong reputation for innovation and scientific expertise. It has established partnerships with numerous leading pharmaceutical and biotech companies. Its competitive advantages include its integrated service offerings, its focus on innovation, and its global presence.

Total Addressable Market (TAM)

The global drug discovery market size is projected to reach $107.7 billion by 2030. Evotec is positioned to capture a significant share of this expanding market through its comprehensive service offerings and strategic partnerships. The Biologics TAM is also significant and growing rapidly.

Upturn SWOT Analysis

Strengths

  • Strong scientific expertise
  • Integrated service offerings
  • Established partnerships with leading pharmaceutical and biotech companies
  • Global presence
  • Strong track record of innovation

Weaknesses

  • Dependence on R&D spending by pharmaceutical and biotech companies
  • Exposure to competition from other CROs and CDMOs
  • Complexity of managing a global organization
  • Impact of macroeconomic events

Opportunities

  • Increasing demand for outsourced drug discovery services
  • Growing adoption of new technologies, such as artificial intelligence and machine learning
  • Expanding into new therapeutic areas
  • Growth in emerging markets

Threats

  • Economic downturns that reduce R&D spending
  • Increased competition from other CROs and CDMOs
  • Regulatory changes that impact drug development
  • Intellectual property risks

Competitors and Market Share

competitor logo Key Competitors

  • Charles River Laboratories (CRL)
  • WuXi AppTec (WX)
  • Thermo Fisher Scientific (TMO)

Competitive Landscape

Evotec possesses a strong integrated platform. However, it faces competition from larger CROs with broader service offerings and geographic reach. Its focus on innovation and strategic partnerships helps it to differentiate itself.

Major Acquisitions

Just Biotherapeutics

  • Year: 2019
  • Acquisition Price (USD millions): 90
  • Strategic Rationale: Expanded Evotec's capabilities in biologics drug discovery and development.

Growth Trajectory and Initiatives

Historical Growth: Evotec has experienced strong revenue growth in recent years, driven by increasing demand for its drug discovery services and its strategic acquisitions.

Future Projections: Analysts project continued revenue growth for Evotec, driven by its strong market position and its investments in new technologies.

Recent Initiatives: Recent initiatives include expanding its genomics capabilities, growing its Just-Evotec Biologics capabilities and strategic partnerships.

Summary

Evotec is a well-positioned drug discovery and development company with strong scientific expertise and integrated service offerings. While it faces competition, its focus on innovation and strategic partnerships provides a competitive edge. Its growth trajectory is promising, driven by increasing demand for outsourced research services. Macro-economic events and R&D funding levels will be key to monitor.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings
  • Industry Reports
  • Analyst Estimates

Disclaimers:

The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available industry reports and estimates. Financial data is subject to change and should be verified with official company filings.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Evotec SE ADR

Exchange NASDAQ
Headquaters -
IPO Launch date 2009-12-04
CEO & Management Board Member Dr. Christian Wojczewski Ph.D.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 4740
Full time employees 4740

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. It has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. The company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.